Product Launches, Investor Conferences, Margin Expansions, and Acquisitions - Research Report on Nu Skin, Avon, Clorox, Estée Lauder, and Prestige Brands

NEW YORK, August 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Nu Skin Enterprises, Inc. (NYSE: NUS), Avon Products, Inc. (NYSE: AVP), The Clorox Co. (NYSE: CLX), Estée Lauder Companies Inc. (NYSE: EL), and Prestige Brands Holdings, Inc. (NYSE: PBH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Nu Skin Enterprises, Inc. Research Report

On August 1, 2013, Nu Skin Enterprises, Inc. (Nu Skin) reported its Q2 2013 financial results. The Company's revenue increased 15.1% YoY to $682.9 million during the quarter. Net income was $74.4 million or $1.22 per diluted share, in Q2 2013 compared to net income of $60.4 million or $0.94 per diluted share, in Q2 2012. Truman Hunt, President and CEO of Nu Skin said, "We are extremely pleased with second-quarter results that reflect the strong momentum of the business. We are particularly pleased with these results given the record regional ageLOC product launches in the prior-year period. Additionally, we generated continued growth of both our consumer and sales leader base, reflected in 32 percent growth in actives and 23 percent growth in sales leaders. Overall, we saw healthy trends throughout the global business, particularly in the Greater China, North Asia and Americas regions." Nu Skin updated its 2013 revenue guidance from previous $2.9 billion to approximately $3.0 billion. The Full Research Report on Nu Skin Enterprises, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4acf_NUS]

--

Avon Products, Inc. Research Report

On August 1, 2013, Avon Products, Inc. (Avon) reported its Q2 2013 financial results. According to the Company, total revenue decreased 2.0% YoY to $2.5 billion during the quarter. Net income attributable to Avon was $31.9 million or $0.07 per diluted share, compared to $61.6 million or $0.14 per diluted share in Q2 2012. Sheri McCoy, CEO of Avon, said, "Our second-quarter results reflect continued progress in stabilizing Avon's business. There is still significant work to be done to deliver sustainable performance in the near and longer term, but I'm pleased with the progress to date. We will succeed by continuing our focus on better serving Avon Representatives, creating a compelling consumer proposition, and simplifying our business to drive both top and bottom line improvements." The Full Research Report on Avon Products, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/676c_AVP]

--

The Clorox Co. Research Report

On August 1, 2013, The Clorox Co. (Clorox) reported its financial results for Q4 FY 2013 and FY 2013 (period ended June 30, 2013). For Q4 FY 2013, the Company's net sales increased 0.4% YoY to $1.5 billion. Net earnings were $183 million or $1.37 per diluted share, compared to net earnings of $174 million or $1.32 per diluted share, in Q4 FY 2012. For FY 2013, net sales increased 2.8% YoY to $5.6 billion. Net earnings were $572 million or $4.30 per diluted share, compared to net earnings of $541 million or $4.09 per diluted share, in FY 2012. Chairman and CEO of Clorox, Don Knauss, said, "We grew sales in all four segments behind product innovation across multiple brands and delivered strong gross margin expansion." For full year 2014, Clorox expects sales to grow by 2% to 4% and diluted EPS to be within $4.55 to $4.70. The Full Research Report on The Clorox Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4ebb_CLX]

--

Estée Lauder Companies Inc. Research Report  

On August 1, 2013, The Estée Lauder Companies Inc. (Estée Lauder) announced that it will release its Q4 FY 2013 and FY 2013 financial results on Thursday, August 15, 2013. The Company also informed that on the same date at 9:00 a.m., Estée Lauder will host a live webcast of its conference call to discuss the results, future prospects, and any recent corporate developments. In a prior announcement on May 2, 2013, the Company released its outlook for FY 2013. The Company expects net sales to grow approximately 6% in constant currency. Further, the Company expects diluted net earnings per share before charges associated with restructuring activities and the impact of early extinguishment of debt to be in the range of $2.56 to $2.61. The Full Research Report on Estée Lauder Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5d80_EL]

--

Prestige Brands Holdings, Inc. Research Report

On August 1, 2013, Prestige Brands Holdings, Inc. (Prestige Brands) reported its financial results for Q1 FY 2014 (period ended June 30, 2013). The Company's total revenues decreased 2.7% YoY to $143.0 million during the quarter. Net income was $20.7 million or $0.40 per diluted share in Q1 FY 2014, compared to net income of $14.7 million or $0.29 per diluted share in Q2 FY 2013. Matthew Mannelly, CEO of Prestige Brands, said, "We are pleased with our performance in the first quarter against our stated strategy to create long-term shareholder value through continued earnings per share growth. In addition, we executed against our M&A strategy with the acquisition of Care Pharmaceuticals, an OTC healthcare products company from New South Wales, Australia." The Full Research Report on Prestige Brands Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09be_PBH]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner